Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352286 | 1.00 | MAPT (0.40) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL6241485 | 0.87 | MAPT (0.35) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL3226013 | 0.80 | IDO1 (0.37) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8905893 | 0.75 | IDO1 (0.33) | IDO1 | |
| SCHEMBL30168823 | 0.75 | IDO1 (0.33) | IDO1 | |
| SCHEMBL27840600 | 0.73 | IDO1 (0.32) | IDO1 | |
| SCHEMBL29941302 | 0.73 | MEN1 (0.39) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL1506868 | 0.73 | MAPT (0.39) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL29350249 | 0.73 | MAPT (0.39) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL6573768 | 0.71 | MEN1 (0.41) | MAPTALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344379-A | Diversity-oriented synthesis and activity research of alpha-carboline and beta-carboline-1-ketone derivatives | 重庆医科大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118344379-A | Diversity-oriented synthesis and activity research of alpha-carboline and beta-carboline-1-ketone derivatives | 重庆医科大学 | 2024-07-16 | — | — | CN | disclosed |
| US-11802129-B1 | Pyrido[3,4-b]indol-1-one compounds as anticancer agents | King Faisal University (SA) | 2023-10-31 | — | — | US | disclosed |
| US-11802129-B1 | Pyrido[3,4-b]indol-1-one compounds as anticancer agents | King Faisal University (SA) | 2023-10-31 | — | — | US | disclosed |
| US-11773092-B1 | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents | King Faisal University (SA) | 2023-10-03 | — | — | US | disclosed |
| EP-3538529-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-9988399-B2 | Bicyclic compounds as ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2018087389-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| EP-2003129-B1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2003129-B1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2003129-A1 | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008147864-A2 | METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
| WO-2006061428-A2 | GABA-A ALPHA 2 AND ALPHA 3 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC, INFLAMMATORY AND MIGRAINE ASSOCIATED PAIN | Universität Zürich (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-4837325-A | Beta-carboline H1 -receptor antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| US-4766124-A | Beta-carbolin H1-receptor antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| US-4663456-A | 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-05 | — | — | US | disclosed |
| US-4120963-A | BLOOD DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPT 1892/4885ALDH1A1 4386/4885LMNA 3942/4885 |
| US-11773092-B1 | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents | IDO1, IDO2, IMPA1 | MAPT 1581/4885ALDH1A1 1039/4885LMNA 2926/4885 |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | MAPT 2076/4885ALDH1A1 3919/4885LMNA 2064/4885 |
| US-11802129-B1 | Pyrido[3,4-b]indol-1-one compounds as anticancer agents | IDO1, TYMP, AURKB | MAPT 1042/4885ALDH1A1 1148/4885LMNA 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.